...
首页> 外文期刊>International journal of oncology >[Corrigendum] The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells
【24h】

[Corrigendum] The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells

机译:[更正]抗肥胖药奥利司他通过激素难治性前列腺癌细胞中的两种不同途径提高对TRAIL的敏感性

获取原文
   

获取外文期刊封面封底 >>

       

摘要

After the publication of the article, the authors noted that in Fig. 5c, the image of β-actin is incorrect. The corrected version of Fig. 5c is shown below. In Fig. 6a, the histogarms are incorrect, and the corrected Fig. 6a is shown below. In Fig. 7, the figure of PrEC is incorrect, and the corrected Fig. 7 (PrEC) is shown below. The corrected figures demonstrate the same findings as the original figures. These corrections do not alter the interpretation of the results and conclusions. [the original article was published in the International Journal of Oncology 40: 1483-1491, 2012; DOI: 10.3892/ijo.2012.1353]
机译:文章发表后,作者注意到,在图5c中,β-肌动蛋白的图像不正确。下面显示了图5c的校正版本。在图6a中,组织树是不正确的,校正后的图6a如下所示。在图7中,PrEC的数字不正确,校正后的图7(PrEC)如下所示。校正后的数字与原始数字具有相同的发现。这些更正不会改变结果和结论的解释。 [原始文章发表于2012年国际肿瘤学杂志40:1483-1491; DOI:10.3892 / ijo.2012.1353]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号